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Strengths and limitations of this study
 ► Pragmatic trial based in injecting equipment pro-
vision sites (IEPS) and designed to fit around the 
needs of people who inject drugs.
 ► Aims to deliver hepatitis C virus diagnosis, eval-
uation and treatment in one site based within the 
community.
 ► Strengthens links with local third-sector organisa-
tions promoting sharing of knowledge which clini-
cians are unlikely to be otherwise able to access.
 ► Trial is being conducted in a single health board; 
National Health Service Tayside in Scotland, UK.
 ► Participants are incentivised to attend treatment by 
way of nutrient drinks and payment of return bus 
fare to the IEPS which may not be available beyond 
the clinical trial setting.
AbStrACt
Introduction Hepatitis C is a blood-borne virus (HCV) 
that can seriously damage the liver and is spread mainly 
through blood-to-blood contact with an infected person. 
Over 85% of individuals who have HCV in Scotland 
became infected following injecting drug use. Since 
people who inject drugs (PWID) are the main source of 
new infections, theoretical modelling has suggested that 
treatment of HCV infection in PWID may effectively reduce 
HCV prevalence and accomplish elimination. This protocol 
describes a clinical trial delivering HCV treatment within 
injecting equipment provision sites (IEPS) in Tayside, 
Scotland.
Methods and analysis PWID attending IEPS are tested 
for HCV and, if they are chronically infected with HCV and 
eligible, invited to receive treatment within the IEPS. They 
are randomised to one of three treatment regimens; daily 
observed treatment, treatment dispensed every 2 weeks 
and treatment dispensed every 2 weeks together with an 
adherence psychological intervention (administered before 
treatment begins). The primary outcome is comparison of 
the rate of successful treatment (SVR
12) in each treatment 
group. Secondary analyses include assessment of 
adherence, reinfection rates, viral resistance to treatment 
and interaction of the treatment with illicit drugs.
Ethics and dissemination The ADVANCE (A Direct 
obserVed therApy versus fortNightly CollEction) HCV 
trial was given favourable opinion by East of Scotland 
Research Ethics Committee (LR/17/ES/0089) prior to 
commencement.
trial registration numbers European Clinical Trials 
Database (EudraCT) (2017-001039-38) and  ClinicalTrials. 
gov (NCT03236506).
IntroduCtIon
Hepatitis C virus (HCV) is a blood-borne 
virus that can seriously damage the liver and 
is spread mainly through blood-to-blood 
contact with an infected person. Globally, 
an estimated 71 million people have chronic 
HCV infection and the WHO has targeted 
elimination of HCV as a public health threat 
by 2030, through reducing new infections 
by 90% and reducing viral hepatitis-related 
deaths by 65%.1 The ‘serious and signifi-
cant public health risk’ posed by HCV was 
recognised during a member’s debate in the 
Scottish Parliament in 2004.2 By December 
2006, Health Protection Scotland estimated 
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that 50 000 persons in Scotland had been infected with 
HCV and that 38 000 were chronically infected.3 4 Esti-
mates in 2017 placed current prevalence in Scotland at 
1% of the population, which increases to 58% among 
those people who inject drugs.5 6 Thus, it is clear that the 
greatest risk of acquiring the virus in the UK is through 
injecting drug use. In Scotland, it is estimated that over 
85% of individuals who have HCV were infected in this 
way.7
The outcome of HCV infection varies considerably 
between individuals. Up to 25% are able to clear the 
infection spontaneously, while the remaining 75% 
become chronically infected.8 Of those chronically 
infected, 10%–20% will develop serious liver disease, 
including cirrhosis and hepatocellular carcinoma, within 
30 years.9 10 Many who are infected are unaware of it, 
and often show no symptoms over a long period of time. 
While there is presently no vaccination for HCV, the 
recent introduction of directly acting antiviral treatments 
(DAA) has begun a new era in treatment of this disease.11 
These new oral treatments are safe, have shorter treat-
ment regimens than previous medications and are effec-
tive, producing a cure in over 95% of cases providing 
adherence is adequate.12
The advent of very effective DAA therapies enables the 
use of treatment as prevention (TaSP), by targeting treat-
ment to people who inject drugs (PWID) who are the 
main source of new infections and reinfections. Imple-
mentation of TaSP strategies to HIV, including scaling up 
treatment and increasing rates of testing, has successfully 
reduced incidence and rate of new HIV infections13 14 
Indeed, modelling work illustrates that HCV treatment 
is a critical component of HCV prevention among PWID 
and is likely to be cost-effective compared with delaying 
treatment or treating non-PWID with mild or moderate 
disease.15–19 For example, Martin et al show that in a popu-
lation where chronic HCV prevalence in PWID is below 
60% and 10–20 per 1000 PWID are treated per year, HCV 
prevalence can be reduced by 10%–80% over 20 years 
depending on the modelling of successful treatment rates 
and retreatment of treatment failures.15 The scale of the 
benefit is inversely and exponentially related to preva-
lence of HCV in the population; the lower the prevalence 
the sooner and larger the impact.15
Conventional treatment pathways focus on treating 
people who no longer inject drugs and tend to engage in 
fewer high-risk behaviours compared with PWID. Treating 
this group will reduce future morbidity in the individuals 
themselves but is unlikely to achieve additional benefit 
in terms of averting future infections, whereas providing 
HCV testing and treatment to PWID is also likely to reduce 
the spread of new infections. Treating this population has 
proved challenging since there are myriad barriers that 
deter PWID from seeking treatment.20 21 These include 
stigma that leads to discrimination against PWID in 
health settings.22 Patients themselves may perceive their 
risk of infection to be low; they may currently be symp-
tomless and may fear the treatment.23 In addition, the 
belief that PWID will demonstrate poor adherence to 
treatment and may have poor rates of successful treat-
ment due to illicit drug or alcohol use has hindered treat-
ment opportunities.22
Over the past 6 years, treatment and care for people with 
HCV living in National Health Service (NHS) Tayside has 
been comprehensively scaled up, and numerous novel 
treatment pathways have been established. Together with 
a conventional hospital-based hepatitis treatment service, 
treatment has also been embedded within the commu-
nity via a combination of NHS and clinical trial-based 
delivery in sites including: addiction treatment centres/
community clinics, community pharmacies,24 prisons and 
injecting equipment provision sites (IEPS).25 Testing and 
treatment is led by specialist nurses with clinician over-
sight as required. DAA regimens that have negligible side 
effects are now the standard of care in conventional treat-
ment populations. DAAs should be taken daily to opti-
mise therapeutic success and therefore if adherence is 
poor, efficacy might be reduced. The rate of successful 
treatments combined with medication cost, reinfection 
rate and emergence of viral resistance will determine if 
this treatment as prevention model is cost-effective with 
DAAs.
This paper describes the ADVANCE (A Direct obserVed 
therApy versus fortNightly CollEction) HCV study 
protocol (V5, 02/04/2018), a clinical trial of investi-
gational medical product delivering DAA treatment 
for HCV to PWID in IEPS in NHS Tayside. These sites 
provide sterile injecting equipment and basic health-
care for PWID including testing and treatment for 
blood-borne viruses by specialist nurses. Signposting 
to other services is also provided, while opioid replace-
ment therapy is not provided. The aim of the study is to 
demonstrate that PWID can successfully be treated for 
HCV using DAA treatment. The effectiveness of three 
different medication dispensing regimens is being deter-
mined by measuring the rates of sustained viral response 
at 12 weeks (SVR12), considered a successful treatment, of 
individuals treated via each regimen. The first regimen 
is directly observed therapy (DOT), the second regimen 
is to provide medication on a fortnightly basis, while the 
third regimen is to provide medication on a fortnightly 
basis together with a 1-hour psychological intervention 
designed to improve adherence, delivered before treat-
ment commences. While DOT is often considered the 
ultimate adherence aid, it has not previously been trialled 
in this patient group, although it has been successfully 
used to treat PWID for HIV infection.26 We hypothesise 
that the fortnightly (with or without adherence) treat-
ment regimens will not be inferior to DOT and will result 
in similar rates of SVR12.
This trial is part of a wider suite of trials and studies 
which will analyse the cost-effectiveness of the TasP 
approach to HCV treatment. The study is underway, 
with the first recruit in January 2018, and recruitment is 
predicted to end in December 2019. Data collection will 
be completed in September 2020.
Library. Protected by copyright.
 o
n
 13 August 2019 at Periodicals Departm
ent Ninewells M
edical
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-029516 on 8 August 2019. Downloaded from 
3Inglis SK, et al. BMJ Open 2019;9:e029516. doi:10.1136/bmjopen-2019-029516
Open access
MEthodS And AnAlySIS
objectives and outcome measures
Primary objective
To compare the efficacy of DAAs in HCV positive, 
active PWID, administered via DOT, fortnightly pick-up 
or fortnightly pick-up with a psychological adherence 
intervention.
Outcome measure
SVR12 rates of participants in the DOT, fortnightly pick-up 
or fortnightly pick-up with a psychological adherence 
intervention group.
Time point of outcome measured
Twelve weeks post-treatment completion.
Study dESIgn
Study set up
Sponsorship is provided via a joint agreement between 
NHS Tayside and the University of Dundee. A clinical trial 
authorisation was provided by the Medicines and Health-
care Products Regulatory Agency in September 2017. 
Overall management of the trial is being provided by the 
Tayside Clinical Trials Unit, a UK Clinical Research Collabo-
ration-registered clinical trials unit.27 The trial is being moni-
tored by the sponsor according to an agreed monitoring 
plan in accordance with the sponsor standard operating 
procedures. Specialist nurses experienced at providing 
HCV treatment within the IEPS were trained in good clin-
ical practice and were given study-specific training. The first 
participant was recuited in January 2018.
design
The study is a parallel three-arm randomised trial 
comparing the efficacy of DAAs for treatment of HCV in 
PWID. The three arms are: (1) DAA dispensed via directly 
observed therapy; (2) DAA dispensed fortnightly and 
(3) DAA dispensed fortnightly following a single-session 
psychological intervention on treatment adherence.
hCV treatment
Participants are treated with Zepatier (a single 150 mg 
tablet comprising 100 mg grazoprevir and 50 mg of 
elbasvir) provided gratis by Merck Sharpe & Dohme. Indi-
viduals infected with HCV genotype 1 are treated with 1 
tablet per day for 12 weeks, as per the marketing authori-
sation for this medication. Individuals infected with geno-
type 3 are treated with 1 tablet of Zepatier, plus 1 tablet of 
Sovaldi (Sofosbuvir 400 mg) purchased via NHS Tayside 
(the local health board) per day for 8 weeks. This is an 
unlicensed treatment combination but has been used 
successfully to treat individuals with genotype 3 infection 
in previous trials.28
Eligibility criteria
The inclusion criteria are deliberately broad and the 
exclusion criteria minimal. This is to ensure that the 
study captures a typical group of PWID using IEPS and 
requiring anti-HCV treatment and is therefore relevant 
to populations in other similar clinics. Almost all infec-
tions within NHS Tayside result from genotype 1 and 3 
HCV.3 Participants who have been treated for HCV with 
DAAs previously are referred to the NHS Tayside multi-
disciplinary team (which includes hepatologists, specialist 
doctors, HCV pharmacists and specialist nurses) for 
review and determination of appropriateness for treat-
ment through the trial.
Inclusion criteria:
 ► Aged 18–70.
 ► HCV PCR confirmed active infection, genotype 1 or 3.
 ► If female, must have negative urine test results for 
pregnancy during initial screening period (for trial 
inclusion) and be advised of limited safety data in 
pregnancy.
 ► Current illicit drug use established through partici-
pant history.
 ► Able to provide informed consent, agreeing to trial 
and clinical monitoring criteria.
Exclusion criteria:
 ► Aggressive or violent behaviour.
 ► Unwilling to consent to general practitioner being 
informed of their participation in the trial.
 ► Pregnancy or breast feeding.
 ► Participation in a drug trial within the previous 30 
days.
 ► Platelet count <75×109/L.
 ► Alanine transaminase >350 U/L.
 ► Clinical history or blood test results consistent with 
decompensated liver failure Childs-Pugh B or C.
 ► Clinical history of primary hepatocellular carcinoma.
 ► Hepatitis B surface antigen positive.
 ► HIV infection.
 ► Hypersensitivity to elbasvir and grazoprevir.
 ► Hypersensitivity to sofosbuvir (genotype 3-infected 
participants ony).
 ► Currently being treated with an inhibitor of organic 
anion transporting polypeptide 1B, for example, 
rifampicin, atazanavir, daruavir, lopinavir, saquinavir, 
tipranavir, cobicistat or ciclosporin.
 ► Currently being treated with inducers of cytochrome 
P450 3A or P-glycoprotein, such as efavirenz, pheny-
toin, carbamazepine, bosentan, etravirine, modafinil 
or St John’s Wort (Hypericum perforatum).
 ► Currently being treated with amiodarone (partici-
pants infected with genotype 3 HCV only).
Enrolment
Individuals attending IEPS are routinely invited to have a 
dry blood spot test (DBST) for HCV. Individuals who have 
had a positive DBST or have previously had a positive PCR 
blood test result for HCV are identified by trained nurses 
working in the IEPS and provided with verbal and written 
information about the trial in the form of a patient infor-
mation sheet. The levels of literacy of some individuals 
in this group are likely to be low, and this was taken into 
account during the preparation of all patient-facing 
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written material. At least 24 hours after being given infor-
mation about the trial, individuals who return to the IEPS 
are asked whether they would like to take part. Some-
times individuals will not return to the IEPS for many days 
or even weeks after receiving information about the trial. 
In these cases, they are reminded about the trial and then 
asked whether they would like to take part. If the partici-
pant is willing, informed consent is obtained by the nurse. 
Ongoing informed consent is checked and documented 
at each study visit.
randomisation
Participants are randomly assigned to treatment regi-
mens using the Tayside Randomisation System (TRuST). 
TRuST is a web-based randomisation system developed 
and maintained by Health Informatics Centre at Univer-
sity of Dundee. Participants are stratified according to 
their gender and HCV genotype.
Visit schedule
All study visits take place within the IEPS which is a 
familiar environment to the people eligible for the trial. 
Visits are conducted by specialist nurses and, in accor-
dance with good clinical practice, trained, delegated 
clinicians sign-off blood test results and eligibility checks. 
Individuals infected with HCV genotype 3 have 8 weeks 
of treatment and attend 4 study visits (table 1). Those 
infected with genotype 1 have 12 weeks of treatment 
and attend 5 study visits (table 1). The extra study visit 
includes blood taken for liver function testing to detect 
any elevated alanine aminotransferase (ALT) levels 
(>350 U/L) that are an occasional side effect of Zepatier 
taken for longer than 8 weeks.29 Any participant with an 
ALT level >350 U/L will have their treatment stopped and 
will be followed up to SVR12.
Since individuals frequently have periods during which 
they do not attend the IEPS, the time periods during 
which visits can take place have deliberately been left 
as long as possible. Occasionally, participants are incar-
cerated during their period on treatment. In this case, 
treatment is transferred to the prison pharmacy and 
the participant’s treatment is maintained by the nurses 
working there with all participants receiving daily treat-
ment. These nurses are part of the clinical hepatitis team 
and operate an established Blood borne virus treatment 
pathway through prisons in the region, headed by the 
study chief investigator which ensures a continuity of care. 
If an individual misses more than seven consecutive doses 
they will be withdrawn from treatment but still followed 
up to the SVR12 visit.
At the baseline visit, blood samples are taken for safety 
tests (including urea and electrolytes, liver function tests, 
full blood count, prothrombin time and pregnancy testing 
for women) and diagnostic tests (HCV PCR and geno-
typing). Baseline demographic information together with 
information about illicit drug habit and social history are 
recorded in the case report form (CRF). To retain as many 
eligible individuals in the study as possible, the blood test 
results and information in the CRF are considered valid 
for 6 months. Therefore, as long as the randomisation 
visit is completed within 6 months of the baseline visit, the 
baseline visit does not need to be repeated. Due to time 
constraints on testing imposed by NHS Tayside laborato-
ries HCV PCR results are valid for 1 year and genotype 
results valid for 5 years.
Patients are randomised to one of the three treatment 
regimens and stratified by sex and genotype of the HCV 
infection.
At the randomisation visit, the participant is told to 
which study arm they have been allocated. A description 
of the three arms is provided below.
At the end of treatment visit, blood samples are taken 
for safety reasons, and information about illicit drug 
use and social situation collected to detect any change 
concomitant with treatment.
At least 12 weeks following the end of treatment, blood 
is taken for the HCV PCR test to measure whether viral 
RNA can be detected.
Blood samples are taken at baseline, end of treatment 
and SVR12 and stored at −80°C. Samples collected from 
individuals who do not achieve SVR12 will be analysed at 
the end of the study for the presence of HCV RNA that 
has mutated to become resistant to DAA.30 A urine sample 
is also collected from individuals at any time while they 
are on treatment and stored at −80°C. These samples may 
be analysed at the end of the study to detect the presence 
of illicit drugs/metabolites that may interact and reduce 
the effectiveness of DAA treatment only for those that do 
not achieve SVR12 despite good adherence to treatment. 
Both blood and urine samples are anonymised and stored 
without personal identifying information. The key that 
removes the anonymisation is held securely, separately 
from the samples, within the clinical team.
DOT treatment regimen
Those in the DOT arm are asked to attend every 
weekday when they are given their tablet and observed 
taking it. Doses for the weekend (and any holidays when 
the IEPS is closed) are given to the participant to take 
away. Travel expenses, in the form of local service, return 
trip bus fare and nutrient drinks are given to encourage 
daily attendance.
Fortnightly treatment regimen
Those randomised to either of the fortnightly dipense 
arms are given a 2-week supply of medication with instruc-
tions to take one dose per day. Participants are asked to 
return any packaging together with untaken medica-
tion to each study visit. Participants who have genotype 
3 HCV receive Sovaldi tablets in bottles that are fitted 
with a Medical Event Monitoring (MEM) cap (Westrock 
Switzerland, MEMS8 TrackCap 38 mm CR). Participants 
are asked to return the caps at the end of treatment, and 
they are scanned to assess participant adherence. Travel 
expenses, for study visits and drug collection days, in the 
form of local service, return trip bus fare and nutrient 
drinks are given to encourage daily attendance.
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Fortnightly treatment regimen with psychological intervention
Participants randomised to receive the psychological inter-
vention designed to promote adherence receive it at the 
randomisation visit before they take their first dose. The 
intervention, which lasts around 1 hour, is based on the 
Information-Motivation-Behavioural (IMB) Skills Model 
of Adherence31 which was originally developed to explain 
adherence behaviour in HIV. Recent research suggests 
this model may have applicability in understanding the 
facilitator and barriers to adherence in patients with 
HCV.32 The model suggests that provision of medication 
information, enhancing personal and social motivation 
and developing behavioural skills linked to determinants 
of adherence may improve adherence in this group. As 
part of the intervention, participants complete a person-
alised booklet, ‘Hepatitis C and Me’, with the guidance 
of their trial nurse. The booklet contains general and 
personalised information on HCV, exercises designed to 
explore and enhance personal and social motivation for 
treatment adherence and a behavioural action plan (the 
skills element of the IMB model). The booklet uses the 
principles of node-link mapping to structure the interven-
tion, using the visual representation of interrelationships 
between thoughts, actions, feelings, triggers of personal 
problems and their hypothetical solutions.33 Participants 
in the other two arms of the trial, who are not receiving 
the psychological intervention, are given the current NHS 
Tayside hepatitis information which provides generalised 
information about HCV without personalised informa-
tion or specific strategies to enhance motivation and 
behavioural skills. Treatment is dispensed as described in 
Fortnightly treatment regimen above.
Sample size calculation
We hypothesise that DAA treatment in active PWID 
administered fortnightly with or without adherence inter-
vention is non-inferior to DOT. Pathways will be compared 
sequentially; DOT versus fortnightly delivery and then 
DOT versus fortnightly pickup with adherence interven-
tion. Fortnightly pick up will be more cost-effective than 
the other two options so long as adherence and efficacy 
matches that of the DOT and fortnightly plus adherence 
intervention. If we assume a 95% SVR12 rate (based on 
published studies, eg, reference 34–36) in the DOT arm of 
the trial in this population and a non-inferiority limit of 
14% which would be likely to maintain clinical effective-
ness, then at a 5% significance level and 90% power, we 
require a sample size of 42 in each group, making 126 in 
total. To allow for dropouts, we will aim to randomise 135 
individuals; 45 per group.
data collection and management
To ensure that participants are not subjected to long study 
visits the number of datapoints collected in the trial has 
deliberately been kept small and limited to fields required 
to answer objectives. Data collected at each study visit is 
entered into a paper CRF. The data are subsequently 
entered into an electronic version of the CRF developed 
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within Openclinica open source software V.3.1.3.1.37 
Data are stored in an anonymised state, identified by trial 
number. No personal information is shared with individ-
uals outwith the local clinical care and research team. A 
key that links trial number to personal identifiers that 
could be used for record linkage is held separately and 
securely on NHS servers.
Safety reporting
Previous experience of recruiting PWID to clinical trials 
has revealed that many have comorbid chronic disease 
and high levels of illness.25 In addition, injuries from 
accident and assault are also common. To ensure that 
safety reporting is restricted to events related to the 
trial, we record as adverse events (AE)s/serious adverse 
events (SAE)s but not report as SAEs in the following 
categories:
 ► Any death or hospitalisation for assault or accidental 
injury.
 ► Hospitalisation for abscesses due to drugs use.
 ► Hospitalisation for wound management due to drugs 
use.
 ► Any death or hospitalisation due to non-HCV 
infection.
 ► Hospitalisation for elective or planned investigation 
or treatment.
 ► Any death or hospitalisation for deteriorating renal 
function, high or low potassium levels.
 ► Any hospitalisation due to nausea, vomiting, constipa-
tion or diarrhoea.
Analysis plan
The primary outcome of SVR12 will be assessed as a binary 
outcome for subjects and so will use logistic regres-
sion modelling. The numerator will be the number of 
subjects achieving SVR12, and the denominator will be 
total number of patients randomised to each arm. Addi-
tionally, results will be expressed as a proportion of the 
estimated HCV-infected subjects using the IEPS. The 
estimated number of infected patients will be based on 
national survey data and the empirical rate discovered 
in the trial (allowing for patients who refuse testing). A 
test of interaction between contingency and pathway will 
be carried out and, if not significant, contingency will 
be assessed independently. If significant, then the effect 
of contingency will be assessed by each pathway sepa-
rately. As all patients will have either achieved SVR12 or 
not, and we will assume that dropouts/lost to follow-up 
are failures, there will be no missing data in the primary 
outcome. Extrabinomial variability or overdispersion will 
be examined in the logistic model and if present alter-
native modelling such as negative binomial models will 
be considered. This will also be adjusted by treatment 
and genotype; the two factors are interdependent deter-
mining length of regimen.
Secondary binary outcomes will be analysed in the same 
procedure, initially as intention to treat with all eligible 
patients as the denominator and then to explore the steps 
in the pathway by per protocol analysis in particular to 
analyse:
a. Proportion of HCV tested who are HCV positive.
b. Proportion of those identified with HCV who start 
HCV treatment within the duration of the study.
c. Adherence in each treatment regimen.
d. Proportion of those initiating treatment who complete 
the treatment course.
e. Reinfection rates (of trial cohort HCV status via na-
tional laboratory testing data for up to 5 years).
Multiple logistic regression modelling will explore the 
patient and pathway characteristics that are associated 
with the secondary outcomes and primary outcome. 
Patient outcomes considered will be age, gender, depri-
vation, employment, comorbidity and the psychosocial 
variables assessed.
Patient and public involvement statement
Patient and public were not involved in the design of 
this study. However, in cognate ongoing studies we are 
conducting interviews with participants to collate their 
experience of the provided through this study.
EthICS And dISSEMInAtIon
The study results will be disseminated through peer-re-
viewed publications, presented at conferences and 
published on  clinicaltrials. gov and Eudract websites. The 
anonymised dataset will be held by the chief investigator. 
Consideration will be given to applications from other 
researchers who apply for access to the data for their own 
research.
Author affiliations
1Tayside Clinical Trials Unit, University of Dundee, Dundee, UK
2School of Social Sciences (Psychology), University of Dundee, Dundee, UK
3Molecular and Clinical Medicine, University of Dundee, Dundee, UK
4Specialist liver service, NHS Tayside, Dundee, UK
5Psychology Department, NHS Fife, Cupar, UK
Acknowledgements The study team acknowledge people who inject drugs within 
Tayside who are participating in the study. In addition health professionals including 
pharmacists, prison workers and the wider clinical team working within NHS 
Tayside. The team also acknowledge MSD who are funding the study.
Contributors SI contributed to study design, wrote the trial protocol, provided 
study-specific training to study team, managed the study and wrote the manuscript. 
LB ran the study, provided study-specific training to study team and revised the 
manuscript CB revised the manuscript and provided study-specific training to study 
team.AM provided the psychological intervention booklet training to study team 
and revised the manuscript.JFD is chief investigatorKG designed the psychological 
intervention and approved the manuscript.EMR delegated clinican on the study and 
revised the manuscriptCS is a specialist nurse who undertook study visitsBS is the 
lead specialist nurse
Funding This study was funded by Merck Sharp and Dohme (grant 
number:53605).
Competing interests SI, CB, AM, LB, ER, CS and KG have no competing interests. 
BS has has received honoraria for lectures from Abbvie, Janssen, Gilead, and MSD. 
JFD has received personal honoraria for lectures and instutional research grants 
from MSD, Abbvie, Gilead, Roche and Janssen. 
Ethics approval Ethical approval was obtained from the East of Scotland Research 
Ethics Service (17/ES/0089; August 2017). The study is being conducted according 
Library. Protected by copyright.
 o
n
 13 August 2019 at Periodicals Departm
ent Ninewells M
edical
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-029516 on 8 August 2019. Downloaded from 
8 Inglis SK, et al. BMJ Open 2019;9:e029516. doi:10.1136/bmjopen-2019-029516
Open access 
to the principles of the Declaration of Helsinki and in accordance with the Research 
Governance Framework Scotland.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCES
 1. Organisation WH. Hepatitis C factsheet, 2018. Available: https://
www. who. int/ news- room/ fact- sheets/ detail/ hepatitis-c
 2. M C. Members' debate on hepatitis C. Edinburgh: Parliament S, 
2004.
 3. Hutchinson SJ, Roy KM, Wadd S, et al. Hepatitis C virus infection in 
Scotland: epidemiological review and public health challenges. Scott 
Med J 2006;51:8–15.
 4. Government S. Hepatitis C action plan for for Scotland phase II: may 
2008-March 2011. Edinburgh, Scotland: Scottish Government, 2008.
 5. Scotland HI. National clinical guidelines for the treatment of HCV in 
adults V5 2018.
 6. Scotland HP. The needle exchange surveillance initiative: prevalence 
of blood-borne viruses and injecting risk behaviours among people 
who inject drugs attending injecting equipment provision services in 
Scotland, 2008-09 to 2015-16. Health Protection Scotland, University 
of the West of Scotland, Glasgow Caledonian University and the 
West of Scotland Specialist Virology Centre, 2017.
 7. Roy KM, Hutchinson SJ, Wadd S, et al. Hepatitis C virus infection 
among injecting drug users in Scotland: a review of prevalence and 
incidence data and the methods used to generate them. Epidemiol 
Infect 2007;135:433–42.
 8. Bonkovsky HL, Mehta S. Hepatitis C: a review and update. J Am 
Acad Dermatol 2001;44:159–82.
 9. O'Brien TR, Yang H-I, Groover S, et al. Genetic factors that affect 
spontaneous clearance of hepatitis C or B virus, response to 
treatment, and disease progression. Gastroenterology 2018.
 10. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 
2014;61(1 Suppl):S58–68.
 11. Jazwinski AB, Muir AJ. Direct-Acting antiviral medications for chronic 
hepatitis C virus infection. Gastroenterol Hepatol 2011;7:154–62.
 12. D'Ambrosio R, Degasperi E, Colombo M, et al. Direct-Acting 
antivirals: the endgame for hepatitis C? Curr Opin Virol 2017;24:31–7.
 13. Montaner JS. Treatment as prevention-a double hat-trick. Lancet 
2011;378:208–9.
 14. Montaner JS, Lima VD, Harrigan PR, et al. Expansion of HAART 
coverage is associated with sustained decreases in HIV/AIDS 
morbidity, mortality and HIV transmission: the "HIV Treatment 
as Prevention" experience in a Canadian setting. PLoS One 
2014;9:e87872.
 15. Martin NK, Vickerman P, Foster GR, et al. Can antiviral therapy for 
hepatitis C reduce the prevalence of HCV among injecting drug user 
populations? A modeling analysis of its prevention utility. J Hepatol 
2011;54:1137–44.
 16. Innes H, Goldberg D, Dillon J, et al. Strategies for the treatment of 
hepatitis C in an era of interferon-free therapies: what public health 
outcomes do we value most? Gut 2015;64:1800–9.
 17. Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and 
future disease burden of hepatitis C among injection drug users in 
Scotland. Hepatology 2005;42:711–23.
 18. Harris RJ, Thomas B, Griffiths J, et al. Increased uptake and new 
therapies are needed to AVERT rising hepatitis C-related end stage 
liver disease in England: modelling the predicted impact of treatment 
under different scenarios. J Hepatol 2014;61:530–7.
 19. Harris RJ, Martin NK, Rand E, et al. New treatments for hepatitis C 
virus (HCV): scope for preventing liver disease and HCV transmission 
in England. J Viral Hepat 2016;23:631–43.
 20. Bruggmann P. Accessing hepatitis C patients who are difficult to 
reach: it is time to overcome barriers. J Viral Hepat 2012;19:829–35.
 21. Swan D, Long J, Carr O, et al. Barriers to and facilitators of hepatitis 
C testing, management, and treatment among current and former 
injecting drug users: a qualitative exploration. AIDS Patient Care 
STDS 2010;24:753–62.
 22. Wolfe D, Luhmann N, Harris M, et al. Human rights and access to 
hepatitis C treatment for people who inject drugs. Int J Drug Policy 
2015;26:1072–80.
 23. Chikovani I, Ompad DC, Uchaneishvili M, et al. On the way 
to hepatitis C elimination in the Republic of Georgia-Barriers 
and facilitators for people who inject drugs for engaging in the 
treatment program: a formative qualitative study. PLoS One 
2019;14:e0216123.
 24. Radley A, de Bruin M, Inglis SK, et al. Clinical effectiveness of 
pharmacy-led versus conventionally delivered antiviral treatment 
for hepatitis C in patients receiving opioid substitution therapy: a 
study protocol for a pragmatic cluster randomised trial. BMJ Open 
2018;8:e021443.
 25. Schulkind J, Stephens B, Ahmad F, et al. High response and re-
infection rates among people who inject drugs treated for hepatitis C 
in a community needle and syringe programme. J Viral Hepat 2018.
 26. Altice FL, Maru DS, Bruce RD, et al. Superiority of directly 
administered antiretroviral therapy over self-administered therapy 
among HIV-infected drug users: a prospective, randomized, 
controlled trial. Clin Infect Dis 2007;45:770–8.
 27. TCTU. Tayside clinical trials unit, 2014. Available: https://www. 
ahspartnership. org. uk/ tasc/ tayside- clinical- trials- unit
 28. Lawitz E, Poordad F, Gutierrez JA, et al. Short-Duration treatment 
with elbasvir/grazoprevir and sofosbuvir for hepatitis C: a 
randomized trial. Hepatology 2017;65:439–50.
 29. Merck. Zepatier tolerability in clinical trials. Available: https://www. 
merckconnect. com/ zepatier/ adverse- reactions. html? hcpUser= yes
 30. Sagnelli E, Starace M, Minichini C, et al. Resistance detection and re-
treatment options in hepatitis C virus-related chronic liver diseases 
after DAA-treatment failure. Infection 2018.
 31. Fisher JD, Fisher WA, Amico KR, et al. An information-motivation-
behavioral skills model of adherence to antiretroviral therapy. Health 
Psychol 2006;25:462–73.
 32. Evon DM, Golin CE, Bonner JE, et al. Adherence during antiviral 
treatment regimens for chronic hepatitis C: a qualitative study 
of patient-reported facilitators and barriers. J Clin Gastroenterol 
2015;49:e41–50.
 33. Dansereau DF, Joe GW, Simpson DD. Node-link mapping: a visual 
representation strategy for enhancing drug abuse counseling. 
Journal of Counseling Psychology 1993;40:385–95.
 34. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir 
for untreated HCV genotype 1 infection. N Engl J Med 
2014;370:1889–98.
 35. Bourliere M, Gordon SC, Flamm SL, et al. Sofosbuvir, Velpatasvir, 
and Voxilaprevir for previously treated HCV infection. N Engl J Med 
2017;376:2134–46.
 36. Poordad F, Felizarta F, Asatryan A, et al. Glecaprevir and pibrentasvir 
for 12 weeks for hepatitis C virus genotype 1 infection and prior 
direct-acting antiviral treatment. Hepatology 2017;66:389–97.
 37. OpenClinica. OpenClinica open source for clinical research. 
Available: https:// openclinica. com/
Library. Protected by copyright.
 o
n
 13 August 2019 at Periodicals Departm
ent Ninewells M
edical
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-029516 on 8 August 2019. Downloaded from 
